融合的途径:抑郁症和阿尔茨海默氏症-共享的病理生理学和新型治疗方法
Shivanshu Bajaj1, Radhakrishnan Mahesh2
1Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani, 333031, Rajasthan, India.
Molecular biology reports
|January 28, 2024
概括
抑郁症和阿尔茨海默病共享重叠的途径,需要超越传统抗抑郁药的新疗法. 人工智能为准确诊断和早期预测这些交织在一起的神经和精神疾病提供了革命性的潜力.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 老年学是一门学科.
背景情况:
- 抑郁症影响全球超过2.8亿人,并且经常与阿尔茨海默病 (AD) 等神经系统疾病同时发生.
- 抑郁症和AD之间重叠的病理生理学 presents显著的研究挑战和治疗限制.
- 目前的抗抑郁药疗法在治疗阿兹海默症患者的并发性抑郁症状方面有效性有限.
研究的目的:
- 探索抑郁症和阿尔茨海默病之间的共同的神经生物学途径.
- 审查针对这些重叠机制的新型治疗策略.
- 突出人工智能在诊断和预测并发性疾病方面的潜力.
主要方法:
- 对神经生物学途径的审查,包括神经氨酸信号传递,HPA轴,亡和神经炎症.
- 讨论传统抗抑郁药以外的新兴治疗类别.
- 探索人工智能应用与神经成像,EEG和生物标志物的结合.
主要成果:
- 确定了抑郁症和AD中重叠的关键神经生物学途径.
- 突出了当前一线抗抑郁药的有限有效性.
- 提出了新的治疗目标和人工智能在临床管理中的变革性作用.
结论:
- 了解共享的病理生理学对于开发对伴随性抑郁症和AD的有效治疗至关重要.
- 针对特定途径的新型治疗剂和人工智能驱动的诊断对于推进护理至关重要.
- 人工智能整合有望提高神经退行性和精神疾病的诊断和早期预测的准确性.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
524
相关概念视频
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Depression: Overview
244
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
244
Antidepressant Drugs: MAOIs and Other Agents
234
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234
Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44
